Given the rarity and often dismal prognosis of uterine sarcomas, the identification of this fusion is of paramount diagnostic importance, as it delineates a distinct entity from its histological mimics and immediately opens avenues for targeted intervention with TRK inhibitors, representing a paradigm shift in the management of this disease. This evidence concerns the gene TPM3 and uterine corpus sarcoma.